Summary
Monoclonal antibodies have been shown to reduce morbidity and mortality in selected subsets of patients with Gram-negative sepsis and/or septic shock. However, the acquisition costs of the antibody products are expected to be in the range of $US3500 to $US4000 per course of therapy and precise identification of patients who will benefit may be difficult. Therefore, the economic impact of these antibodies will be significant. We have performed a model cost-effectiveness and cost-benefit analysis specific to our institution based on previously reported mortality figures. Our data suggest that the cost-effectiveness of HA-1A (Centoxin®) will be comparable with that of a variety of commonly used medical interventions, but will produce an incremental increase in costs of at least $US7000 per patient because of the acquisition cost of the drug. as well as an increase in numbers of survivors whose hospitalisation will be prolonged.
Similar content being viewed by others
References
Barriere SL, Guglielmo BJ. Gram-negative sepsis. The sepsis syndrome, and the role of antiendotoxin monoclonal antibodies. Clinical Pharmacy 11(3): 223–235, 1992
Baumgartner JD. Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal. Infectious Diseases Clinics of North America 5(4): 915–927, 1991
Bone RC. A critical evaluation of new agents for the treatment of sepsis. Journal of the American Medical Association 266(12): 1686–1691, 1991
Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. Journal of the American Medical Association 266(8): 1097–1102, 1991
Nash DB, Johnson NE, Gottlieb JE, Vlasses PH. Monoclonal antibodies for septic shock: in or out of the barn door? Quality Review Bulletin 11(10): 310–313, 1991
Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-venous thrombosis in major orthopedic surgery. Journal of the American Medical Association 257: 203–208, 1987
Oster G, Epstein AM. Cost-effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease. Journal of the American Medical Association 258: 2381–2387, 1987
Schulman KA, Glick HA, Rubin H, Eisenberg JM. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Journal of the American Medical Association 266(24): 3466–3471, 1991
Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Annals of Internal Medicine 116(3): 238–244, 1992
van Deventer SJ, Buller HR, Ten Cate JW. Endotoxemia: an early predictor of septicemia in febrile patients. Lancet 1: 605–609, 1988
Wenzel R, Bone R, Fein A, Quenzer R, Schentag J, et al. Results of a second double-blind, randomized controlled trial of antiendotoxin antibody E5 in Gram-negative sepsis. Progress Abstracts of the 31st Interscience Conference on Antimicrobial Agents in Chemotherapy, Abstract 1170, American Society for Microbiology, Washington DC; Oct 2, 1991
Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, et al. Treatment of Gram-negative bacteraemia and septic shock with HA-1A human monoclonal antibody against endotoxin. New England Journal of Medicine 324(7): 429–436, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barriere, S.L. The Economic Impact of HA-1A (Centoxin) Against Endotoxin. PharmacoEconomics 2, 408–413 (1992). https://doi.org/10.2165/00019053-199202050-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199202050-00008